Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3D189 in Hematologic Malignancies
NCT05320809Phase 1Completed
- Sponsor
- 3D Medicines Inc.
- Start
- Aug 2022
- Primary completion
- Nov 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of galinpepimut-s in acute leukemia, multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by 3D Medicines Inc. Primary endpoints: Treatment-Related Adverse Events at 13 months and Immune response rate at 12 months. Started Aug 2022; status: completed.
02
Drugs
galinpepimut-s
03
Conditions
acute leukemiamultiple myeloma (MM)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05320809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320809.